达格列净与射血分数轻度降低或保留心衰中的表观难治性高血压:DELIVER试验
DELIVER试验事后分析纳入6263例射血分数>40%的心衰患者,按基线血压分为控制组、非难治性高血压组和表观难治性高血压(aTRH)组。aTRH占11.5%,合并症更多且肾功能更差;达格列净在各血压组中获益一致,aTRH组绝对事件下降幅度最大(4.1/100患者年),且耐受性良好。
要点
- aTRH在射血分数>40%心衰中占11.5%,合并症多、肾功能差。
- 达格列净在各血压组获益一致,aTRH组绝对事件下降最大。
- 达格列净轻度降低收缩压约1-3 mmHg,不增加低血压风险。
核心结论
- 在射血分数>40%的心衰患者中,aTRH占11.5%,达格列净在各血压组中一致改善临床结局且耐受性良好。
研究设计与样本
- DELIVER试验事后分析,纳入6263例射血分数>40%的心衰患者,按基线血压分为控制组、非难治性高血压组和aTRH组。
主要发现
- aTRH组占11.5%,合并更多心血管代谢合并症,左室射血分数倾向更高且肾功能更差。
- 主要结局(心血管死亡或心衰恶化事件)发生率:控制组8.7/100患者年,非难治性高血压组8.5/100患者年,aTRH组9.5/100患者年。
- 达格列净对主要结局的相对获益在各血压组间一致(P交互=0.114)。
- aTRH组达格列净绝对事件下降幅度最大(4.1/100患者年),非难治性高血压组2.7/100患者年,控制组0.8/100患者年。
- aTRH组无论治疗分组,随访期间血管事件(包括心梗和卒中)报告率更高。
关键数值与推荐
- aTRH定义:使用包括利尿剂在内的3种降压药后,血压仍≥140/90 mmHg(糖尿病者≥130/80 mmHg)。
- 非难治性高血压定义:血压高于阈值但不符合aTRH标准。
- 控制血压定义:血压低于阈值。
- 达格列净使收缩压降低约1-3 mmHg,不增加低血压、低血容量或其他严重不良事件风险,但未改善aTRH患者血压达标比例。
临床怎么用
- 对射血分数>40%的心衰合并aTRH患者,达格列净可一致改善临床结局且耐受性良好。
- 达格列净轻度降低收缩压约1-3 mmHg,不增加低血压风险,但不应期望其改善血压达标率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. In this post hoc analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure), we evaluated clinical profiles and treatment effects of dapagliflozin among participants with aTRH. METHODS: DELIVER participants were categorized on the basis of baseline blood pressure (BP), with aTRH defined as BP ≥140/90 mm Hg (≥130/80 mm Hg if diabetes) despite treatment with 3 antihypertensive drugs including a diuretic. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. Controlled BP was defined as BP under threshold. Incidence of the primary outcome (cardiovascular death or worsening heart failure event), key secondary outcomes, and safety events was assessed by baseline BP category. RESULTS: Among 6263 DELIVER participants, 3766 (60.1%) had controlled BP, 1779 (28.4%) had nonresistant hypertension, and 718 (11.5%) had aTRH at baseline. Participants with aTRH had more cardiometabolic comorbidities and tended to have higher left ventricular ejection fraction and worse kidney function. Rates of the primary outcome were 8.7 per 100 patient-years in those with controlled BP, 8.5 per 100 patient-years in the nonresistant hypertension group, and 9.5 per 100 patient-years in the aTRH group. Relative treatment benefits of dapagliflozin versus placebo on the primary outcome were consistent across BP categories (Pinteraction=0.114). Participants with aTRH exhibited the greatest absolute reduction in the rate of primary events with dapagliflozin (4.1 per 100 patient-years) compared with nonresistant hypertension (2.7 per 100 patient-years) and controlled BP (0.8 per 100 patient-years). Irrespective of assigned treatment, participants with aTRH experienced a higher rate of reported vascular events, including myocardial infarction and stroke, over study follow-up. Dapagliflozin modestly reduced systolic BP (by ≈1 to 3 mm Hg) without increasing risk of hypotension, hypovolemia, or other serious adverse events, irrespective of BP category, but did not improve the proportion of participants with aTRH attaining goal BP over time. CONCLUSIONS: aTRH was identified in >1 in 10 patients with heart failure and left ventricular ejection fraction >40% in DELIVER. Dapagliflozin consistently improved clinical outcomes and was well-tolerated, including among those with aTRH. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03619213.
引用
- Ostrominski JW, Vaduganathan M, Selvaraj S, et al. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation. 2023. PMID: 37830208. doi:10.1161/CIRCULATIONAHA.123.065254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。